Lung Cancer Clinical Trials & Research at Providence Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
Providence Medical Group is currently enrolling patients for the following
lung cancer clinical trials:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
A Phase lb Multicenter, Open-label Dose-escalation Study to Evaluate the
Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab
in Combination with Cisplatin, Carboplatin or Pemetrexed in First-line
Treatment of Patients with Advanced or Metastatic Non-squamous Non-small
Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2
Overexpression (HER2+) (DESTINY-Lung03)
Treatment agent: Trastuzumab deruxtecan + durvalumab, carboplatin, or pemetrexed
PI:
Ian Anderson, MD
Study Coordinator: Melissa Phillips // Melissa.Phillips2@stjoe.org// (707)
521-3833 ext. 1313
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT03328026
Sponsor: AstraZeneca
Study to Assess the Effect of PF_06946860 on Appetite Following Subcutaneous
Administration to Patients with Anorexia and Advanced Cancer
Treatment agent: PF-06946860
PI: Sara Keck, MD
Study Coordinator: Tracy Foster
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04803305?term=PF-06946860&draw=2&rank=2
Sponsor: Pfizer
A Phase III, Randomized, Multicenter, 3-Arm Study of Neoadjuvant Osimertinib
as Monotherapy or in Comination with Chemotherapy versus Standard of Care
Chemotherapy Alone for the Treatment of Patients with Epidermal Growth
Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer
(NeoADAURA)
Treatment agent: Chemotherapy + Osimbertinib or placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy
Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable
Non-Small Cell Lung Cancer - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Non-Small Cell Lung Cancer
A phase III, multicenter, randomized, double blind, placebo-controlled
study evaluating the efficacy and safety of canakinumab versus placebo
as adjuvant therapy in adult subjects with stages AJCC/UICC v. 8 II-IIIA
and IIIB (T>5cm N2) completely resected (R0) non-small cell lung cancer (NSCLC)
Treatment agent: Canakinumab or Placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: Novartis Pharmaceuticals
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients
with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Treatment agent: MRTX849 + pembrolizumab
PI:
Manasa Vulchi, MD
Study Coordinator: Tracy Foster
Resources and Links:
clinicaltrials.gov NCT No: NCT04613596
Sponsor: Mirati Therapeutics, Inc.
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants
With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)
Treatment agent: Zimberelimab with or without domvanalimab and/or etrumadenant
PI:
Ian Anderson, MD
Study Coordinator: Camille Shaffer
Resources and Links:
clinicaltrials.gov NCT No: NCT04262856
Sponsor: Arcus Biosciences, Inc.
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled
Study to Determine the Efficacy of Adjuvant Durvalumab in Combination
with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC
(MeRmaiD-1)
Treatment agent: Durvalumab + chemotherapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04385368
Sponsor: AstraZeneca
A Phase III, Open-label, Randomized Study of Osimertinib with or without
Platinum Plus Pemetrexed Chemotherapy, as First-line Treatment in Patients
with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive, Locally
Advanced or Metastatic Non-small Cell Lung Cancer (FLAURA2)
Treatment agent: Osimertinib with or without platinum-based chemotherapy
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT04035486
Sponsor: AstraZeneca
Small Cell Lung Cancer
A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled
Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with
Minimal Residual Disease Following Surgery and Curative Intent Therapy
(MERMAID-2)
Treatment agent: Durvalumab or placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04642469?term=04642469&draw=2&rank=1
Sponsor: AstraZeneca
A Phase II, Open-label, Single-arm Study of Berzosertib (M6620) in Combination
With Topotecan in Participants With Relapsed Platinum-resistant Small-Cell
Lung Cancer (DDRiver SCLC 250)
Treatment agent: Berzosertib, Topotecan Hydrochloride
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04768296?term=DDRiver&draw=2&rank=1
Sponsor: EMD Serono
Seer-020201 (Pulmonary Nodules)
Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI:
Manasa Vulchi, MD
Study Coordinator: Melissa
NCT – NA
A Randomized Phase 3 Study of MRTX849 versus Docetaxel in Patients with
Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation
Treatment: MRTX849, Docetaxel
PI:
Ian Anderson, MD
Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836 ext. 1136
Resources and Links:
https://clinicaltrials.gov/ct2/show/NCT04685135?term=krystal-12&draw=2&rank=1
Sponsor: Mirati Therapeutics